Can you take Lifileucel with Rilonacept?

Lifileucel has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Patients treated with lifileucel have exhibited cardiac disorders. Prior to administration of lifileucel, assess patients for a history of cardiac/vascular disorders or for current use of anticoagulants. Monitor patients with signs and symptoms of cardiac disorders before and after infusion of lifileucel.

Lifileucel has a moderate potential interaction with Heart Disease.

Patients treated with lifileucel have exhibited cardiac disorders. Prior to administration of lifileucel, assess patients for a history of cardiac/vascular disorders or for current use of anticoagulants. Monitor patients with signs and symptoms of cardiac disorders before and after infusion of lifileucel.

Rilonacept has a moderate potential interaction with High Cholesterol.

Patients treated with rilonacept experienced increases in their mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. The mean increases from baseline for total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were 19 mg/dL, 2 mg/dL, 10 mg/dL, and 57 mg/dL respectively after 6 weeks of open-label therapy. Physicians should monitor the lipid profiles of their patients especially those with hyperlipidemias, and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.

Lifileucel has a moderate potential interaction with History - Myocardial Infarction.

Patients treated with lifileucel have exhibited cardiac disorders. Prior to administration of lifileucel, assess patients for a history of cardiac/vascular disorders or for current use of anticoagulants. Monitor patients with signs and symptoms of cardiac disorders before and after infusion of lifileucel.

Lifileucel has a moderate potential interaction with Infection.

Lifeleucel should not be administered to patients with active infection or inflammatory disorders. Monitor patients for signs or symptoms of infection before and after infusion of lifileucel; treat appropriately as indicated. Administer prophylactic antimicrobials according to institutional guidelines.

Rilonacept has a moderate potential interaction with Infection.

Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with other medication as rilonacept, that work through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking rilonacept compared with placebo. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with an active or chronic infection. Additionally, latent tuberculosis can be reactivated and should be treated before initiating therapy with rilonacept.

Rilonacept has a moderate potential interaction with Liver Disease.

No formal studies have been conducted to examine the pharmacokinetics of rilonacept administered subcutaneously in patients with hepatic impairment. Caution is advised if used on these patients.

Lifileucel has a moderate potential interaction with Pulmonary Impairment.

Patients treated with lifileucel may develop worsened respiratory function. Prior to administration of lifileucel, assess patients for a history of respiratory disorders. Monitor patients with signs and symptoms of respiratory failure before and after infusion of lifileucel. Withhold or discontinue lifileucel infusion if severe acute respiratory failure is evidenced.

Lifileucel has a moderate potential interaction with Renal Dysfunction.

Patients treated with lifileucel may develop worsened renal function. Prior to administration of lifileucel, assess patients for a history of renal impairment. Monitor patients with signs and symptoms of acute renal failure before and after infusion of lifileucel. Withhold or discontinue lifileucel infusion if severe acute renal injury is evidenced.

Rilonacept has a moderate potential interaction with Renal Dysfunction.

No formal studies have been conducted to examine the pharmacokinetics of rilonacept administered subcutaneously in patients with renal impairment. Caution is advised if used on these patients.

Rilonacept has a moderate potential interaction with Tuberculosis, Latent.

Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with other medication as rilonacept, that work through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking rilonacept compared with placebo. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with an active or chronic infection. Additionally, latent tuberculosis can be reactivated and should be treated before initiating therapy with rilonacept.

Rilonacept has a major potential interaction with Vaccination.

Live vaccines should not be given concurrently with rilonacept. Rilonacept may interfere with normal immune response to new antigens; therefore, vaccinations may not be effective in patients receiving rilonacept. No data are available on the effectiveness of vaccination with inactivated (killed) antigens in patients receiving rilonacept. Because IL-1 blockade may interfere with immune response to infections, it is recommended that prior to initiation of therapy with rilonacept adult and pediatric patients receive all recommended vaccinations, as appropriate, including pneumococcal vaccine and inactivated influenza vaccine.